MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $133.14 million. The enterprise value is $44.70 million.
| Market Cap | 133.14M |
| Enterprise Value | 44.70M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 103.21 million shares outstanding. The number of shares has increased by 0.95% in one year.
| Current Share Class | 103.21M |
| Shares Outstanding | 103.21M |
| Shares Change (YoY) | +0.95% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 56.16% |
| Float | 93.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.19 |
| Forward PS | 4.18 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.26, with a Debt / Equity ratio of 0.11.
| Current Ratio | 12.26 |
| Quick Ratio | 11.08 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -20.39% and return on invested capital (ROIC) is -11.17%.
| Return on Equity (ROE) | -20.39% |
| Return on Assets (ROA) | -10.64% |
| Return on Invested Capital (ROIC) | -11.17% |
| Return on Capital Employed (ROCE) | -19.70% |
| Weighted Average Cost of Capital (WACC) | 11.16% |
| Revenue Per Employee | $341,220 |
| Profits Per Employee | -$391,604 |
| Employee Count | 91 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.82 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.97% in the last 52 weeks. The beta is 1.53, so MaxCyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | -5.97% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.13 |
| Relative Strength Index (RSI) | 49.89 |
| Average Volume (20 Days) | 828,651 |
Short Selling Information
The latest short interest is 1.23 million, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 1.23M |
| Short Previous Month | 1.24M |
| Short % of Shares Out | 1.19% |
| Short % of Float | 1.31% |
| Short Ratio (days to cover) | 1.27 |
Income Statement
In the last 12 months, MaxCyte had revenue of $31.05 million and -$35.64 million in losses. Loss per share was -$0.33.
| Revenue | 31.05M |
| Gross Profit | 24.60M |
| Operating Income | -34.43M |
| Pretax Income | -35.64M |
| Net Income | -35.64M |
| EBITDA | -30.29M |
| EBIT | -34.43M |
| Loss Per Share | -$0.33 |
Balance Sheet
The company has $105.69 million in cash and $17.25 million in debt, with a net cash position of $88.44 million or $0.86 per share.
| Cash & Cash Equivalents | 105.69M |
| Total Debt | 17.25M |
| Net Cash | 88.44M |
| Net Cash Per Share | $0.86 |
| Equity (Book Value) | 158.75M |
| Book Value Per Share | 1.50 |
| Working Capital | 111.38M |
Cash Flow
In the last 12 months, operating cash flow was -$22.98 million and capital expenditures -$665,000, giving a free cash flow of -$23.64 million.
| Operating Cash Flow | -22.98M |
| Capital Expenditures | -665,000 |
| Depreciation & Amortization | 4.14M |
| Net Borrowing | n/a |
| Free Cash Flow | -23.64M |
| FCF Per Share | -$0.23 |
Margins
Gross margin is 79.23%, with operating and profit margins of -110.88% and -114.77%.
| Gross Margin | 79.23% |
| Operating Margin | -110.88% |
| Pretax Margin | -114.77% |
| Profit Margin | -114.77% |
| EBITDA Margin | -97.54% |
| EBIT Margin | -110.88% |
| FCF Margin | n/a |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.95% |
| Shareholder Yield | -0.95% |
| Earnings Yield | -27.40% |
| FCF Yield | -18.18% |
Analyst Forecast
The average price target for MaxCyte is $4.11, which is 218.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.11 |
| Price Target Difference | 218.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 9.86% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 1.46 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.46 |
| Piotroski F-Score | 2 |